

Robert G Gish

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/625151/publications.pdf>

Version: 2024-02-01

318
papers

15,351
citations

14655

66
h-index

20358

116
g-index

328
all docs

328
docs citations

328
times ranked

14610
citing authors

#	ARTICLE	IF	CITATIONS
1	A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2006, 354, 1001-1010.	27.0	1,345
2	Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment. <i>Gastroenterology</i> , 2004, 127, 485-492.	1.3	447
3	American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. <i>Gastroenterology</i> , 2015, 148, 221-244.e3.	1.3	432
4	A multicenter United Statesâ€”Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. <i>Hepatology</i> , 2001, 33, 424-432.	7.3	389
5	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	343
6	Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. <i>Hepatology</i> , 1998, 27, 213-222.	7.3	324
7	Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B. <i>Gastroenterology</i> , 2007, 133, 1437-1444.	1.3	324
8	Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.. <i>Journal of Clinical Investigation</i> , 1991, 88, 270-281.	8.2	302
9	Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. <i>Hepatology</i> , 1999, 29, 1581-1586.	7.3	281
10	Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. <i>Hepatology</i> , 2006, 44, 915-924.	7.3	278
11	Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and posttreatment with interferon alfa. <i>Hepatology</i> , 1996, 24, 6-9.	7.3	270
12	Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nilotrexed or Doxorubicin. <i>Journal of Clinical Oncology</i> , 2007, 25, 3069-3075.	1.6	249
13	A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients. <i>Gastroenterology</i> , 2005, 129, 1198-1209.	1.3	247
14	Severe Hepatotoxicity Associated with Nevirapine Use in HIVâ€”Infected Subjects. <i>Journal of Infectious Diseases</i> , 2005, 191, 825-829.	4.0	225
15	Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 6413-6418.	7.1	224
16	Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1 1Gilead Sciences gratefully acknowledges the patients, investigators, and study site personnel who participated in clinical trials GS-98-437 and GS-98-438.. <i>Gastroenterology</i> , 2003, 125, 107-116.	1.3	221
17	Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. <i>Antiviral Research</i> , 2015, 121, 47-58.	4.1	216
18	Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. <i>Gastroenterology</i> , 2003, 124, 925-932.	1.3	202

#	ARTICLE	IF	CITATIONS
19	Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study. <i>Hepatology</i> , 2013, 57, 881-889.	7.3	195
20	A model to predict severe HCV-related disease following liver transplantation. <i>Hepatology</i> , 2003, 38, 34-41.	7.3	190
21	Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. <i>Hepatology</i> , 2007, 46, 324-329.	7.3	177
22	Model for end-stage liver disease (MELD) exception guidelines: Results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. <i>Liver Transplantation</i> , 2006, 12, S128-S136.	2.4	167
23	Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. <i>American Journal of Gastroenterology</i> , 2003, 98, 2060-2063.	0.4	165
24	Keratin 8 Mutations in Patients with Cryptogenic Liver Disease. <i>New England Journal of Medicine</i> , 2001, 344, 1580-1587.	27.0	163
25	Is chronic hepatitis B being undertreated in the United States?. <i>Journal of Viral Hepatitis</i> , 2011, 18, 377-383.	2.0	153
26	A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	7.3	139
27	Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. <i>Journal of General Virology</i> , 2004, 85, 811-820.	2.9	135
28	Hepatitis C virus as a systemic disease: reaching beyond the liver. <i>Hepatology International</i> , 2016, 10, 415-423.	4.2	131
29	Selection of chronic hepatitis B therapy with high barrier to resistance. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 341-353.	9.1	127
30	Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B*. <i>Journal of Viral Hepatitis</i> , 2010, 17, 16-22.	2.0	125
31	Changing nomenclature for PBC: From "cirrhosis"™ to "cholangitis"™. <i>Hepatology</i> , 2015, 62, 1620-1622.	7.3	125
32	Survival After Liver Transplantation in Patients With Hepatic Iron Overload: The National Hemochromatosis Transplant Registry. <i>Gastroenterology</i> , 2005, 129, 494-503.	1.3	121
33	The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons. <i>Value in Health</i> , 2008, 11, 527-538.	0.3	118
34	Elevated Alpha-Fetoprotein. <i>Clinics in Liver Disease</i> , 2015, 19, 309-323.	2.1	118
35	Characteristics of Hepatitis B Virus Isolates of Genotype G and Their Phylogenetic Differences from the Other Six Genotypes (A through F). <i>Journal of Virology</i> , 2002, 76, 6131-6137.	3.4	116
36	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. <i>Antiviral Research</i> , 2015, 121, 97-108.	4.1	116

#	ARTICLE	IF	CITATIONS
37	Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. <i>Hepatology</i> , 2002, 35, 922-929.	7.3	114
38	Chronic hepatitis B: What should be the goal for new therapies?. <i>Antiviral Research</i> , 2013, 98, 27-34.	4.1	112
39	Fetal microchimerism alone does not contribute to the induction of primary biliary cirrhosis. <i>Hepatology</i> , 1999, 30, 833-838.	7.3	111
40	Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon- β 1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. <i>Hepatology</i> , 2007, 45, 569-578.	7.3	108
41	Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study. <i>Journal of Hepatology</i> , 2005, 43, 60-66.	3.7	100
42	Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>Gastroenterology</i> , 2015, 149, 1627-1629.	1.3	96
43	Coinfection with hepatitis B and D: Epidemiology, prevalence and disease in patients in Northern California. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1521-1525.	2.8	95
44	Hepatitis Delta: Epidemiology, Diagnosis and Management 36 Years After Discovery. <i>Current Gastroenterology Reports</i> , 2014, 16, 365.	2.5	94
45	Prevalence of Chronic Hepatitis B Virus Infection in the United States. <i>American Journal of Gastroenterology</i> , 2020, 115, 1429-1438.	0.4	92
46	A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. <i>Hepatology</i> , 2002, 36, 1253-1258.	7.3	91
47	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019, 70, 1008-1015.	3.7	90
48	Treating HCV with ribavirin analogues and ribavirin-like molecules. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 8-13.	3.0	88
49	Long-term follow-up of patients diagnosed with alcohol dependence or alcohol abuse who were evaluated for liver transplantation. <i>Liver Transplantation</i> , 2001, 7, 581-587.	2.4	86
50	Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. <i>Liver Transplantation</i> , 2006, 12, S105-S107.	2.4	86
51	Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. <i>Cancer</i> , 2016, 122, 2512-2523.	4.1	86
52	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Journal of Hepatology</i> , 2015, 63, 1285-1287.	3.7	85
53	Are infectious agents involved in primary biliary cirrhosis? A PCR approach. <i>Journal of Hepatology</i> , 1999, 31, 664-671.	3.7	84
54	RNA Interference Therapy With ARCA520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020, 72, 19-31.	7.3	84

#	ARTICLE	IF	CITATIONS
55	MINIMAL CRITERIA FOR PLACEMENT OF ADULTS ON THE LIVER TRANSPLANT WAITING LIST. <i>Transplantation</i> , 1998, 66, 956-962.	1.0	84
56	Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasia. <i>Liver Transplantation</i> , 2006, 12, S95-S97.	2.4	82
57	Mycophenolate Mofetil in Autoimmune Hepatitis Patients Not Responsive or Intolerant to Standard Immunosuppressive Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 799-802.	4.4	82
58	Similar Risk of Renal Events Among Patients Treated With Tenofovir or Entecavir for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 941-946.	4.4	81
59	Rate of natural disease progression in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2003, 38, 307-314.	3.7	80
60	Survival After Liver Transplantation in Patients With Hepatic Iron Overload: The National Hemochromatosis Transplant Registry. <i>Gastroenterology</i> , 2005, 129, 494-503.	1.3	78
61	Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. <i>Liver International</i> , 2007, 27, 1394-1401.	3.9	78
62	Determination of hepatitis B virus genotype G by polymerase chain reaction with hemi-nested primers. <i>Journal of Virological Methods</i> , 2001, 98, 153-159.	2.1	76
63	Model for end-stage liver disease (MELD) exception for portopulmonary hypertension. <i>Liver Transplantation</i> , 2006, 12, S114-S116.	2.4	76
64	T1653 Mutation in the Box a Increases the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Genotype C Infection. <i>Clinical Infectious Diseases</i> , 2006, 42, 1-7.	5.8	73
65	Chronic Hepatitis B: Current Testing Strategies. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 666-676.	4.4	70
66	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	7.3	70
67	Safety, Tolerability, and Pharmacokinetics of ARCA520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 350-362.	1.6	69
68	Global HBV burden: guesstimates and facts. <i>Hepatology International</i> , 2018, 12, 315-329.	4.2	68
69	Characterization of Hepatitis G Virus (GB-C Virus) Particles: Evidence for a Nucleocapsid and Expression of Sequences Upstream of the E1 Protein. <i>Journal of Virology</i> , 1998, 72, 2738-2744.	3.4	68
70	Development of Hepatocellular Carcinoma in Autoimmune Hepatitis Patients: A Case Series. <i>Digestive Diseases and Sciences</i> , 2011, 56, 578-585.	2.3	66
71	Eight genotypes (A-H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics. <i>Journal of Medical Virology</i> , 2004, 73, 516-521.	5.0	64
72	An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States. <i>Hepatology</i> , 2021, 74, 607-626.	7.3	64

#	ARTICLE	IF	CITATIONS
73	Model for end-stage liver disease (MELD) exception guidelines. <i>Liver Transplantation</i> , 2006, 12, S85-S87.	2.4	63
74	The Impact of Race/Ethnicity on the Clinical Epidemiology of Autoimmune Hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 155-161.	2.2	61
75	Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 743-753.	8.1	60
76	Hepatocellular Carcinoma: Overcoming Challenges in Disease Management. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 252-261.	4.4	57
77	Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 173-185.	3.0	57
78	Optimization for the detection of hepatitis C virus antigens in the liver. <i>Journal of Hepatology</i> , 1994, 20, 143-147.	3.7	56
79	Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. <i>Journal of Medical Virology</i> , 2006, 78, 1296-1303.	5.0	56
80	Chronic Hepatitis B Infection. <i>Clinics in Liver Disease</i> , 2012, 16, 347-369.	2.1	54
81	Model for end-stage liver disease (MELD) exception for polycystic liver disease. <i>Liver Transplantation</i> , 2006, 12, S110-S111.	2.4	52
82	Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications. <i>World Journal of Gastroenterology</i> , 2012, 18, 498.	3.3	52
83	A Pilot Study of Extended Duration Peginterferon Alfa-2a for Patients With Hepatitis B e Antigen-Negative Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2007, 102, 2718-2723.	0.4	50
84	Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. <i>Cancer Biomarkers</i> , 2012, 11, 161-171.	1.7	49
85	Long-term follow-up after liver transplantation in patients with hepatic iron overload. <i>Liver Transplantation</i> , 1999, 5, 369-374.	1.8	47
86	Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study. <i>Journal of Hepatology</i> , 2007, 47, 51-59.	3.7	47
87	Alcoholic Liver Disease. <i>Clinics in Liver Disease</i> , 2016, 20, 563-580.	2.1	47
88	Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. <i>Liver Transplantation</i> , 2014, 20, n/a-n/a.	2.4	46
89	Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 52-62.	8.1	45
90	Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. <i>Journal of Virological Methods</i> , 2003, 110, 29-35.	2.1	44

#	ARTICLE	IF	CITATIONS
91	PS-052-End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. <i>Journal of Hepatology</i> , 2019, 70, e32.	3.7	44
92	Chronic Hepatitis B: A Critical Appraisal of Current Approaches to Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 233-248.	4.4	43
93	Safety and efficacy of viremagine versus ribavirin in ViSER2: Randomized, double-blind study in therapy-naïve hepatitis C patients. <i>Journal of Hepatology</i> , 2010, 52, 32-38.	3.7	43
94	Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B. <i>Pharmacoeconomics</i> , 2007, 25, 963-977.	3.3	42
95	The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: Notes from a recent workshop. <i>Cancer Biomarkers</i> , 2008, 4, 19-33.	1.7	41
96	Immunosuppression in Patients with Chronic Hepatitis B. <i>Current Hepatology Reports</i> , 2014, 13, 235-244.	0.9	41
97	Portal Vein Thrombosis. <i>Clinics in Liver Disease</i> , 2015, 19, 199-221.	2.1	41
98	A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma. <i>Hepatology Communications</i> , 2022, 6, 1753-1763.	4.3	41
99	Novel Changes in Glycosylation of Serum Apo-J in Patients with Hepatocellular Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1222-1229.	2.5	36
100	Changing nomenclature for PBC: From "cirrhosis"™ to "cholangitis"™. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, e57-e59.	1.5	36
101	Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States. <i>Hepatology</i> , 2015, 62, 1339-1341.	7.3	33
102	Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. <i>Journal of Hepatology</i> , 1995, 22, 257-262.	3.7	32
103	One-step real-time PCR assay for detection and quantitation of hepatitis D virus RNA. <i>Journal of Virological Methods</i> , 2013, 193, 531-535.	2.1	32
104	Management of hepatitis C virus in special populations: Patient and treatment considerations. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 311-318.	4.4	31
105	Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 1240-1252.	3.7	31
106	The impact of pretransplant hepatic encephalopathy on survival following liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 873-880.	2.4	31
107	Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 707-716.	3.1	31
108	AUTOIMMUNE LIVER DISEASE. <i>Clinics in Liver Disease</i> , 2001, 5, 287-314.	2.1	30

#	ARTICLE	IF	CITATIONS
109	De Novo Non-Alcoholic Fatty Liver Disease Following Orthotopic Liver Transplantation. <i>American Journal of Transplantation</i> , 2003, 3, 1413-1417.	4.7	30
110	Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>American Journal of Gastroenterology</i> , 2015, 110, 1536-1538.	0.4	30
111	A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation. <i>Journal of Viral Hepatitis</i> , 2014, 21, 905-908.	2.0	29
112	Drugs in Development for Hepatitis B. <i>Drugs</i> , 2017, 77, 1263-1280.	10.9	29
113	Classifying genotype F of hepatitis B virus into F1 and F2 subtypes. <i>World Journal of Gastroenterology</i> , 2005, 11, 6295.	3.3	29
114	The NS5A Replication Complex Inhibitors: Difference Makers?. <i>Clinics in Liver Disease</i> , 2011, 15, 627-639.	2.1	28
115	Liver disease in Viet Nam: Screening, surveillance, management and education: A 5-year plan and call to action. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 238-247.	2.8	28
116	Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. <i>BMJ Open Gastroenterology</i> , 2015, 2, e000032.	2.7	28
117	Changing nomenclature for PBC: from "cirrhosis" to "cholangitis". <i>Gut</i> , 2015, 64, 1671-1672.	12.1	28
118	Future Therapies for Hepatitis C. <i>Antiviral Therapy</i> , 2006, 11, 397-408.	1.0	28
119	Successful Domino Liver Transplantation from a Patient with Methylmalonic Acidemia. <i>JIMD Reports</i> , 2015, 25, 87-94.	1.5	27
120	Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study. <i>BMJ Open</i> , 2019, 9, e028248.	1.9	27
121	PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold. <i>Journal of Hepatology</i> , 2019, 70, e51-e52.	3.7	27
122	Clinical Trial Results of New Therapies for HBV: Implications for Treatment Guidelines. <i>Seminars in Liver Disease</i> , 2005, 25, 29-39.	3.6	26
123	Hepatocellular Carcinoma Surveillance: A National Survey of Current Practices in the USA. <i>Digestive Diseases and Sciences</i> , 2014, 59, 3073-3077.	2.3	25
124	Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. <i>World Journal of Gastroenterology</i> , 2015, 21, 4644-4651.	3.3	25
125	Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. <i>Gut</i> , 2022, 71, 789-797.	12.1	25
126	Current Treatment and Future Directions in the Management of Chronic Hepatitis B Viral Infection. <i>Clinics in Liver Disease</i> , 2005, 9, 541-565.	2.1	24

#	ARTICLE	IF	CITATIONS
127	Model for end-stage liver disease (MELD) exception for bacterial cholangitis. <i>Liver Transplantation</i> , 2006, 12, S91-S92.	2.4	24
128	The Effector Domain of MARCKS Is a Nuclear Localization Signal that Regulates Cellular PIP2 Levels and Nuclear PIP2 Localization. <i>PLoS ONE</i> , 2015, 10, e0140870.	2.5	24
129	RNA Interference and Its Potential Applications to Chronic HBV Treatment: Results of a Phase I Safety and Tolerability Study. <i>Antiviral Therapy</i> , 2011, 16, 547-554.	1.0	23
130	Cellular mechanics of germ band retraction in <i>Drosophila</i> . <i>Developmental Biology</i> , 2013, 384, 205-213.	2.0	23
131	Differential Reductions in Viral Antigens Expressed from CCCDNA Integrated DNA in Treatment Na ⁺ ve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520. <i>Journal of Hepatology</i> , 2016, 64, S390-S391.	3.7	23
132	Global Perspective on Hepatitis B Virus Infections in the Era of Effective Vaccines. <i>Clinics in Liver Disease</i> , 2019, 23, 383-399.	2.1	23
133	Improving outcomes for patients with chronic hepatitis B. <i>Current Gastroenterology Reports</i> , 2007, 9, 14-22.	2.5	22
134	A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. <i>Hepatology International</i> , 2009, 3, 480-489.	4.2	22
135	Future Therapy for Hepatitis B Virus: Role of Immunomodulators. <i>Current Hepatology Reports</i> , 2016, 15, 237-244.	0.9	22
136	Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. <i>Liver Transplantation</i> , 2016, 22, 1356-1366.	2.4	22
137	Views of US Voters on Compensating Living Kidney Donors. <i>JAMA Surgery</i> , 2016, 151, 710.	4.3	21
138	Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival. <i>Journal of Hepatology</i> , 2016, 64, 326-332.	3.7	21
139	Sodium benzoate for treatment of hepatic encephalopathy. <i>Gastroenterology and Hepatology</i> , 2013, 9, 219-27.	0.1	21
140	Elevated Expression of Tyrosine Kinase DDR2 in Primary Biliary Cirrhosis. <i>Autoimmunity</i> , 2002, 35, 521-529.	2.6	20
141	Inhibition of Hec1 as a novel approach for treatment of primary liver cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 511-520.	2.3	20
142	Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1089-1097.	2.0	20
143	Hepatitis B in liver transplant recipients. <i>Liver Transplantation</i> , 2006, 12, S54-S64.	2.4	19
144	Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemic. <i>Journal of Viral Hepatitis</i> , 2011, 18, e40-51.	2.0	19

#	ARTICLE	IF	CITATIONS
145	Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , 1995, 40, 2595-2601.	2.3	18
146	Model for end-stage liver disease (MELD) exception for hereditary hemorrhagic telangiectasia. <i>Liver Transplantation</i> , 2006, 12, S108-S109.	2.4	18
147	Editorial: To "Be" or Not to "Be": That Is the Question. <i>American Journal of Gastroenterology</i> , 2009, 104, 1948-1952.	0.4	18
148	Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2009, 16, 784-789.	2.0	18
149	Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naïve patients treated with entecavir. <i>Antiviral Therapy</i> , 2013, 18, 691-698.	1.0	18
150	Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen. <i>Journal of Hepatology</i> , 2017, 66, S27.	3.7	18
151	Model for end-stage liver disease (MELD) exception for hepatic encephalopathy. <i>Liver Transplantation</i> , 2006, 12, S102-S104.	2.4	17
152	Chronic HBV infection outside treatment guidelines: is treatment needed?. <i>Antiviral Therapy</i> , 2012, 18, 229-235.	1.0	17
153	Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis. <i>PLoS ONE</i> , 2019, 14, e0220612.	2.5	17
154	Hepatocellular Carcinoma: Molecular and Genomic Guideline for the Clinician. <i>Clinics in Liver Disease</i> , 2011, 15, 307-321.	2.1	16
155	A Clinical Assessment of Wilson Disease in Patients With Concurrent Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 267-273.	2.2	16
156	Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1867-1869.	4.4	16
157	Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States. <i>Journal of Viral Hepatitis</i> , 2019, 26, 350-361.	2.0	16
158	A review of liver transplantation for the dentist and guidelines for dental management. <i>Special Care in Dentistry</i> , 1993, 13, 74-80.	0.8	15
159	Genotyping and Genomic Sequencing in Clinical Practice. <i>Clinics in Liver Disease</i> , 2007, 11, 761-795.	2.1	15
160	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Digestive and Liver Disease</i> , 2015, 47, 924-926.	0.9	15
161	Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States. <i>Journal of Viral Hepatitis</i> , 2017, 24, 17-21.	2.0	15
162	Hepatitis B treatment: Current best practices, avoiding resistance. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, S14-S19.	1.3	15

#	ARTICLE	IF	CITATIONS
163	The <sc>NAFLD–</sc>MAFLD</sc> debate: Is there a Consensus–Consensus methodology?. Liver International, 2022, 42, 742-748.	3.9	15
164	Ascending Multiple–Dose Pharmacokinetics of Virodine, a Prodrug of Ribavirin, in Adult Subjects With Compensated Hepatitis C Infection. Journal of Clinical Pharmacology, 2005, 45, 275-285.	2.0	14
165	<sc>U</sc>nited <sc>N</sc>etwork for <sc>O</sc>rgan <sc>S</sc>haring regional variations in appeal denial rates with non–standard Model for End–Stage Liver Disease/Pediatric End–Stage Liver Disease exceptions: support for a national review board. Clinical Transplantation, 2015, 29, 513-522.	1.6	14
166	Hepatitis B Core Antibody: Role in Clinical Practice in 2020. Current Hepatology Reports, 2020, 19, 254-265.	0.9	14
167	Model for end-stage liver disease (MELD) exception for cystic fibrosis. Liver Transplantation, 2006, 12, S98-S99.	2.4	13
168	Clinical outcomes of liver transplantation for HBV–related hepatocellular carcinoma: data from the NIH HBV OLT study. Clinical Transplantation, 2011, 25, E152-62.	1.6	13
169	Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease. Therapeutic Advances in Gastroenterology, 2016, 9, 887-897.	3.2	13
170	Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia. Liver International, 2018, 38, 451-457.	3.9	13
171	Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. Gastroenterology and Hepatology, 2016, 12, 293-9.	0.1	13
172	Model for end-stage liver disease (MELD) exception for Budd-Chiari syndrome. Liver Transplantation, 2006, 12, S93-S94.	2.4	12
173	Do we need to MEND the MELD?. Liver Transplantation, 2007, 13, 486-487.	2.4	11
174	Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C. Liver International, 2007, 27, 1111-1118.	3.9	11
175	Current Treatment Guidelines for Chronic Hepatitis B and Their Applications. Journal of Clinical Gastroenterology, 2014, 48, 773-783.	2.2	11
176	Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment. Hepatology International, 2016, 10, 624-631.	4.2	11
177	Treatment of Chronically HBV-Infected Chimpanzees with RNA Interference Therapeutic ARC-520 LED to Potent Reduction of Viral MRNA, DNA and Proteins without Observed Drug Resistance. Journal of Hepatology, 2016, 64, S398.	3.7	11
178	Markov modeling in hepatitis B screening and linkage to care. Theoretical Biology and Medical Modelling, 2017, 14, 11.	2.1	11
179	Diagnostics of Hepatitis B Virus: Standard of Care and Investigational. Clinical Liver Disease, 2018, 12, 5-11.	2.1	11
180	Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. BMJ Open Gastroenterology, 2019, 6, e000256.	2.7	11

#	ARTICLE	IF	CITATIONS
181	MAFLD and Cardiovascular Events: What Does the Evidence Show?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2025-2028.	4.4	11
182	Treating hepatitis C: the state of the art. <i>Gastroenterology Clinics of North America</i> , 2004, 33, 1-9.	2.2	10
183	More Severe Deficits in Performance Status at Time of Liver Transplant is Associated With Significantly Higher Risk of Death Following Liver Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e392-e399.	2.2	10
184	Model for end-stage liver disease (MELD) exception for ascites. <i>Liver Transplantation</i> , 2006, 12, S88-S90.	2.4	9
185	Model for end-stage liver disease (MELD) exception for primary hyperoxaluria. <i>Liver Transplantation</i> , 2006, 12, S117-S118.	2.4	9
186	Society of interventional radiology critique and commentary on the cochrane report on transarterial chemoembolization. <i>Hepatology</i> , 2013, 57, 1675-1676.	7.3	9
187	Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. <i>Translational Cancer Research</i> , 2013, 2, 460-471.	1.0	9
188	Acute liver failure in adults: an evidence-based management protocol for clinicians. <i>Gastroenterology and Hepatology</i> , 2012, 8, 161-212.	0.1	9
189	Hepatocellular carcinoma (HCC): current and evolving therapies. <i>IDrugs: the Investigational Drugs Journal</i> , 2008, 11, 198-203.	0.7	9
190	Transmission of hepatitis B virus through allotransplantation. <i>Liver Transplantation</i> , 1996, 2, 161-164.	1.8	8
191	Future Directions in the Treatment of Patients with Chronic Hepatitis C Virus Infection. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1999, 13, 57-62.	1.7	8
192	Model for end-stage liver disease (MELD) exception for portal hypertensive gastrointestinal bleeding. <i>Liver Transplantation</i> , 2006, 12, S112-S113.	2.4	8
193	Customizing the Management of Chronic Hepatitis B Virus Infection. <i>Seminars in Liver Disease</i> , 2007, 27, 009-017.	3.6	8
194	Duplication of MER115 on chromosome 4 in patients with primary biliary cirrhosis. <i>Liver International</i> , 2009, 29, 375-383.	3.9	8
195	High rate of core promoter and precore mutations in patients with chronic hepatitis B. <i>Hepatology International</i> , 2015, 9, 209-217.	4.2	8
196	Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States. <i>Journal of Immigrant and Minority Health</i> , 2021, 23, 1267-1279.	1.6	8
197	GB Virus C (GBV-C/HGV) and E2 Antibodies in Children Pre-liver and Post-liver Transplant. <i>Pediatric Research</i> , 1999, 45, 795-798.	2.3	8
198	Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 374-382.	1.4	8

#	ARTICLE	IF	CITATIONS
199	A multidisciplinary approach to the management of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2010, 6, 1-16.	0.1	8
200	Treatment of chronic hepatitis B: New antiviral therapies. <i>Current Gastroenterology Reports</i> , 1999, 1, 20-26.	2.5	7
201	Model for end-stage liver disease (MELD) exception for uncommon hepatic tumors. <i>Liver Transplantation</i> , 2006, 12, S122-S123.	2.4	7
202	Model for end-stage liver disease (MELD) exception for unusual metabolic liver diseases. <i>Liver Transplantation</i> , 2006, 12, S124-S127.	2.4	7
203	Model for end-stage liver disease (MELD) exception small-for-size syndrome. <i>Liver Transplantation</i> , 2006, 12, S120-S121.	2.4	7
204	Hepatocellular Carcinoma: Locoregional and Targeted Therapies. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 599-610.	2.2	7
205	Chronic hepatitis B virus in the Philippines. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 945-952.	2.8	7
206	A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population. <i>Journal of Hepatology</i> , 2017, 66, S265.	3.7	7
207	Epidemiology and Natural History of Chronic Hepatitis B Virus Infection. , 2018, , 63-89.		7
208	Normal alkaline phosphatase levels are dependent on race/ethnicity: NationalGEP Health and Nutrition Examination Survey data. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000502.	2.7	7
209	Global trends and the impact of chronic hepatitis B and C on <scp>disabilityâ€adjusted</scp> life years. <i>Liver International</i> , 2022, 42, 2145-2153.	3.9	7
210	Model for end-stage liver disease (MELD) exception for severe pruritus. <i>Liver Transplantation</i> , 2006, 12, S119-S119.	2.4	6
211	Recent developments in the treatment of chronic hepatitis B virus infection. <i>Expert Opinion on Investigational Drugs</i> , 1995, 4, 95-115.	4.1	5
212	Characterization of anti-hepatitis C virus-positive sera not genotyped by restriction fragment length polymorphism or serology. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 339-344.	2.8	5
213	Model for end-stage liver disease (MELD) exception for familial amyloidotic polyneuropathy. <i>Liver Transplantation</i> , 2006, 12, S100-S101.	2.4	5
214	Improving outcomes for patients with chronic hepatitis B. <i>Hepatology Research</i> , 2007, 37, S67-S78.	3.4	5
215	1007 RISK OF RENAL TOXICITY WITH TENOFOVIR DF (TDF) FOR CHRONIC HEPATITIS B (CHB). <i>Journal of Hepatology</i> , 2010, 52, S388-S389.	3.7	5
216	Clinical Management and Case Reports for the Treatment of Hepatocellular Carcinoma With Sorafenib. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 733-737.	2.2	5

#	ARTICLE	IF	CITATIONS
217	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. Clinics in Liver Disease, 2019, 23, 487-492.	2.1	5
218	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. Gastroenterology and Hepatology, 2013, 9, 1-24.	0.1	5
219	Is there a serological difference between men and women with primary biliary cirrhosis?. American Journal of Gastroenterology, 1999, 94, 2482-2486.	0.4	4
220	Letter to the editors. Liver Transplantation, 2005, 11, 366-366.	2.4	4
221	Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment. AIDS Research and Therapy, 2011, 8, 29.	1.7	4
222	Medical interventions associated with HBV reactivation: Common and less common. Clinical Liver Disease, 2015, 5, 32-34.	2.1	4
223	Sofosbuvir/Ledipasvir without Ribavirin in the Treatment of Asians with Chronic Hepatitis C Virus Genotype 6 in the United States: Community-Based Real World Outcomes. Journal of Hepatology, 2016, 64, S815-S816.	3.7	4
224	Predicting HBsAg Clearance Responses during ARC-520 RNA Interference (RNAi) Therapy Based on HBsAg Epitope Profile Analysis. Journal of Hepatology, 2016, 64, S602.	3.7	4
225	Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?. Expert Review of Anti-Infective Therapy, 2016, 14, 41-56.	4.4	4
226	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. Clinics in Liver Disease, 2019, 23, 493-509.	2.1	4
227	Hepatitis C Vaccination: Where We Are and Where We Need to Be. Pathogens, 2021, 10, 1619.	2.8	4
228	Calcium compartmentation and exchange rates in primary hepatocyte culture. Analytical Biochemistry, 1990, 187, 187-196.	2.4	3
229	759 IMPACT OF ENTECAVIR VERSUS LAMIVUDINE ON HEPATIC COVALENTLY CLOSED-CIRCULAR DNA AND TOTAL HEPATIC HBVDNA IN NUCLEOSIDE-NAÏVE HBeAg POSITIVE CHRONIC HEPATITIS B PATIENTS. Journal of Hepatology, 2013, 58, S308-S309.	3.7	3
230	Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona. BMJ Open Gastroenterology, 2017, 4, e000158.	2.7	3
231	Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b. Hepatology Research, 2021, 51, 156-165.	3.4	3
232	Low Prevalence of Vaccination or Documented Immunity to Hepatitis A and Hepatitis B Viruses Among Individuals with Chronic Liver Disease. American Journal of Medicine, 2021, 134, 882-892.	1.5	3
233	[563] PREDICTIVE VALUE FOR LOW LEVEL HEPATIC FIBROSIS IN CHRONIC HEPATITIS C (CMC) PATIENTS: COMPARISON OF FIVE NON-INVASIVE INDICES. Journal of Hepatology, 2007, 46, S214.	3.7	2
234	Diagnosis of Chronic Hepatitis B and the Implications of Viral Variants and Mutations. American Journal of Medicine, 2008, 121, i-OBC.	1.5	2

#	ARTICLE	IF	CITATIONS
235	Comparable efficacy with entecavir monotherapy and tenofovir+entecavir combination in chronic hepatitis B patients. <i>BMJ Open Gastroenterology</i> , 2015, 2, e000030.	2.7	2
236	Primary Care Physicians Utilizing the Echo Model Equally Effective as Subspecialists Treating HCV using Direct-Acting Antivirals-Only Regimens: Results of the Echo Model. <i>Journal of Hepatology</i> , 2016, 64, S818-S819.	3.7	2
237	Diversity of clinical presentation and virological characteristics of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International network. <i>Journal of Hepatology</i> , 2017, 66, S257-S258.	3.7	2
238	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. <i>Clinics in Liver Disease</i> , 2019, 23, 511-519.	2.1	2
239	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. <i>Clinics in Liver Disease</i> , 2019, 23, 521-534.	2.1	2
240	Point of Care Diagnostic Testing for Hepatitis B Virus. <i>Current Hepatology Reports</i> , 2020, 19, 245-253.	0.9	2
241	Surgical Treatment of Hepatocellular Carcinoma: Resection Versus Transplantation. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2016, , 73-84.	0.0	2
242	Monotherapy vs multiple-drug therapy: The experts debate. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, S20-S24.	1.3	2
243	Hepatocellular Carcinoma: Current Questions and Future Directions. <i>Gastroenterology and Hepatology</i> , 2015, 11, 182-5.	0.1	2
244	Hepatitis D Virus: A Call to Screening. <i>Gastroenterology and Hepatology</i> , 2014, 10, 647-86.	0.1	2
245	HBV/HCV Coinfection and Possible Reactivation of HBV Following DAA Use. <i>Gastroenterology and Hepatology</i> , 2017, 13, 292-295.	0.1	2
246	Letter to the editor: Importance of universal screening for chronic hepatitis B infection in adults in the United States. <i>Hepatology</i> , 2022, 75, 1062-1063.	7.3	2
247	An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus. <i>Journal of Clinical Gastroenterology</i> , 2022, Publish Ahead of Print, .	2.2	2
248	Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review. <i>Cells</i> , 2022, 11, 1998.	4.1	2
249	Hepatitis C and hepatocellular carcinoma in African Americans. <i>Gastroenterology</i> , 2000, 118, A1435.	1.3	1
250	Failure to identify specific sequence variations in genotype 1b HCV NS58 associated with response to interferon/ribavirin therapy. <i>Gastroenterology</i> , 2001, 120, A367.	1.3	1
251	Studying the Treatment of Chronic Hepatitis B Viral Infection in Special Populations. , 2004, 96, 465-498.		1
252	Maximizing the benefits of antiviral therapy for HCV: the advantages of treating side effects. <i>Gastroenterology Clinics of North America</i> , 2004, 33, xxiii-xxiv.	2.2	1

#	ARTICLE	IF	CITATIONS
253	Treating HCV with ribavirin analogues and ribavirin-like molecules. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 488-488.	3.0	1
254	Improving clinical trial design for hepatocellular carcinoma treatments. <i>Oncology Reviews</i> , 2007, 1, 45-52.	1.8	1
255	Chronic Hepatitis B Viral Infection. , 0, , 2112-2138.		1
256	LP55 : Response guided therapy is not dead: Low Sustained Virologic Response (SVR) rates in patients who have detectable Hepatitis C Virus (HCV) at week 4 of treatment with SOFOSBUVIR (SOF) containing regimens. <i>Journal of Hepatology</i> , 2015, 62, S290.	3.7	1
257	Low Sustained Virologic Response (SVR) Rates in Genotype (GT) 2 and 3 Patients with Quantifiable Hepatitis C Virus (HCV) at Week 4 of Treatment with Sofosbuvir (SOF) Containing Regimens. <i>Journal of Hepatology</i> , 2016, 64, S786.	3.7	1
258	The Prevalence of Non-Alcoholic Steatohepatitis among Diabetic Patients Followed by Primary Care and Endocrinology. <i>Journal of Hepatology</i> , 2016, 64, S486.	3.7	1
259	Identification of recombinant strains in <sc>HCV</sc> genotype 1 and 3: Is it needed?. <i>Liver International</i> , 2018, 38, 958-958.	3.9	1
260	Significant Hepatic Fibrosis Among Treatment-Naive Chronic Hepatitis B Virus With Increased Hepatitis B Virus DNA and Normal Alanine Aminotransferase. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 146-148.	4.4	1
261	We Are All Africans: A Highly Personal Migratory View of the History of Hepatitis B. <i>Clinical Liver Disease</i> , 2020, 16, 24-33.	2.1	1
262	Autoimmune Hepatitis in Cuban Patients: A Retrospective Analysis of Clinical and Histological Profiles, Treatments, and Outcomes. <i>Current Therapeutic Research</i> , 2020, 93, 100594.	1.2	1
263	Geographic regions with high prevalence of nonalcoholic steatohepatitis-related hepatic fibrosis are also observed to demonstrate high prevalence of metabolic disease risk factors and low consumption of fruits and vegetables. <i>Clinical Nutrition Experimental</i> , 2020, 30, 15-26.	2.0	1
264	Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection. <i>Gastroenterology and Hepatology</i> , 2016, 12, 679-689.	0.1	1
265	Risk Factors and Treatment for Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2006, 2, 477-478.	0.1	1
266	Medical therapies to extend survival in hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 1-14; quiz 15.	0.3	1
267	Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 2 p preceding 4-15.	0.3	1
268	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11 Suppl 5, 1-22; quiz 2 p following p22.	0.3	1
269	Editorial: tenofovir alafenamide fumarate“a new silver bullet to prevent mother-to-child transmission of hepatitis B virus. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1744-1745.	3.7	1
270	Variation in Antibody Reactivity to the Hepatitis C Virus by Comparative Immunoscreening and Enzyme Immunoassay. <i>Viral Immunology</i> , 1993, 6, 49-54.	1.3	0

#	ARTICLE	IF	CITATIONS
271	Chemo-embolization for treatment of hepatocellular carcinoma discovered while awaiting liver transplantation: A two-center experience. <i>Gastroenterology</i> , 2000, 118, A1010-A1011.	1.3	0
272	"Delayed" HCV RNA clearance on rebetron therapy: A comparison of week 12 responders VS. late responders. <i>Gastroenterology</i> , 2000, 118, A947.	1.3	0
273	Keratin 8 mutations in patient with cryptogenic liver disease. <i>Gastroenterology</i> , 2001, 120, A45.	1.3	0
274	Potential reduction of post-transplantation HCV-related disease progression by a better selection of the donor. <i>Journal of Hepatology</i> , 2002, 36, 175-176.	3.7	0
275	Epidemiological and clinical differences between hepatitis B virus genotype B with and without recombination with genotype C. <i>Gastroenterology</i> , 2003, 124, A761-A762.	1.3	0
276	Hepatitis B in Liver Transplant Recipients as a Special Model of Antiviral Drug Development. , 2004, 96, 319-342.		0
277	Entecavir. <i>Drugs</i> , 2006, 66, 1623-1624.	10.9	0
278	787 NEGATIVE TISSUE PCR DOES NOT CONFER REDUCED RISK OF RELAPSE AFTER TREATMENT OF HCV IN PATIENTS POST-LIVER TRANSPLANT. <i>Journal of Hepatology</i> , 2008, 48, S294.	3.7	0
279	W1012 Treatment of Hepatitis C Associated Severe Mixed Cryoglobulinemic Syndrome with Plasma Exchange Improves Tolerability and Response to Interferon-Based Therapy. <i>Gastroenterology</i> , 2008, 134, A-832.	1.3	0
280	The new epidemiology of hepatitis B in the United States. <i>Current Hepatitis Reports</i> , 2009, 8, 3-9.	0.3	0
281	W1811 HBV Screening in Asian Pacific Islander Americans: An Interim Analysis of the Hep B Free Program. <i>Gastroenterology</i> , 2009, 136, A-867.	1.3	0
282	W1816 HBV Management Among US Clinicians: Gaps in Clinical Competence and Practice Performance—Survey Findings. <i>Gastroenterology</i> , 2009, 136, A-868.	1.3	0
283	T1002 Clinical Epidemiology of Wilson Disease in Patients with Concurrent Liver Disease. <i>Gastroenterology</i> , 2009, 136, A-844.	1.3	0
284	469 Decline in Hepatitis B Surface Antigen Levels With Entecavir Treatment in HBeAg-Positive Nucleoside Naïve Chronic Hepatitis B Patients-Results From Phase III Study ETV-022. <i>Gastroenterology</i> , 2012, 142, S-917.	1.3	0
285	Su2034 Inhibition of Hec-1 as a Novel Approach to the Treatment of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2012, 142, S-978.	1.3	0
286	HCV In At Risk Populations: Who Can be Treated and How?. <i>Current Hepatitis Reports</i> , 2012, 11, 1-9.	0.3	0
287	516 Impact of Entecavir Versus Lamivudine on Hepatic Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Naïve HBeAg Positive Chronic Hepatitis B Patients. <i>Gastroenterology</i> , 2013, 144, S-950.	1.3	0
288	Mo1047 HCC Surveillance: An Inquiry Into Current Practices in the United States. <i>Gastroenterology</i> , 2014, 146, S-995.	1.3	0

#	ARTICLE	IF	CITATIONS
289	Spontaneous Regression of HCC: A Case Report. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, e112.	4.4	0
290	Unilateral Sensori-Neural Hearing Loss Induced by Pegylated Interferon $\hat{I}\pm 2a$: A Case Report. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, e113.	4.4	0
291	Sa1854 Birth Cohort-Specific Disparities in Hepatocellular Carcinoma (HCC) Outcomes: Individuals Born Between 1945 to 1965 Have Higher Rates of HCC With Milan Criteria, Higher Rates of HCC Treatment, and Significantly Higher Long-Term Survival. <i>Gastroenterology</i> , 2015, 148, S-1025.	1.3	0
292	953 Race/Ethnicity-Specific Disparities in Cancer Incidence, Burden of Disease, and Overall Survival Among Patients With Hepatocellular Carcinoma in the U.S.: An Updated Analysis of the Surveillance, Epidemiology, and End Results Cancer Registry. <i>Gastroenterology</i> , 2015, 148, S-185.	1.3	0
293	Tu1653 Bringing HCV Treatment to the Community: Preliminary Clinical Outcomes of an FQHC-based HCV Treatment Program. <i>Gastroenterology</i> , 2016, 150, S1157.	1.3	0
294	Chronic Hepatitis B Viral Infection. , 2016, , 387-391.		0
295	High Rates of Surface Antigen Loss and Sustained Viral Suppression in Asian Chronic Hepatitis B Patients Treated with Oral Antiviral Therapy: Community-Based Real World Outcomes. <i>Journal of Hepatology</i> , 2016, 64, S601.	3.7	0
296	424 Development of a Community-Based Testing, Linkage, and Hepatitis C Treatment Program. <i>Gastroenterology</i> , 2016, 150, S1033.	1.3	0
297	Treatment outcomes of hepatitis C virus recombinant form 2k/1b with sofosbuvir based regimens in Georgia. <i>Journal of Hepatology</i> , 2017, 66, S302-S303.	3.7	0
298	Sa1516 - Widening Disparities in Model for End Stage Liver Disease Scores at Time of Liver Transplant Waitlist Registration and at Time of Liver Transplantation: an Analysis of the 2005-2016 United Network for Organ Sharing Registry Data. <i>Gastroenterology</i> , 2018, 154, S-1139-S-1140.	1.3	0
299	Entecavir versus other oral antiviral drugs for chronic hepatitis B. <i>The Cochrane Library</i> , 0, , .	2.8	0
300	Su1472 - African Americans and Patients with Alcoholic Liver Disease have Significantly Higher Model for end Stage Liver Disease (MELD) Scores at Time of Waitlist Registration and at Time of Liver Transplantation. <i>Gastroenterology</i> , 2018, 154, S-531.	1.3	0
301	LBP-38-Increasing Number of Metabolic Co-Morbidities are Associated with Higher Risk of Advanced Fibrosis in Patients with Nonalcoholic Steatohepatitis. <i>Journal of Hepatology</i> , 2019, 70, e160.	3.7	0
302	SAT-494-Global hepatocellular carcinoma mortality trends: An analysis of the world health organization cancer mortality database. <i>Journal of Hepatology</i> , 2019, 70, e851-e852.	3.7	0
303	Tu1185 OLDER AGE AND PRESENCE OF ADVANCED FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE PATIENTS IS ASSOCIATED WITH SIGNIFICANTLY GREATER HEALTHCARE RESOURCE UTILIZATION OF RADIOLOGY SERVICES. <i>Gastroenterology</i> , 2020, 158, S-1010.	1.3	0
304	Mo1459 SEX-SPECIFIC AND RACE/ETHNICITY-SPECIFIC DIFFERENCES IN PERFORMANCE CHARACTERISTICS OF NON-INVASIVE SEROLOGICAL SCORING SYSTEMS TO PREDICT ADVANCED FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE PATIENTS. <i>Gastroenterology</i> , 2020, 158, S-1411.	1.3	0
305	Improving clinical trial design for hepatocellular carcinoma treatments. <i>Oncology Reviews</i> , 2011, 1, .	1.8	0
306	Improving clinical trial design for hepatocellular carcinoma treatments. <i>Oncology Reviews</i> , 2011, 1, 45.	1.8	0

#	ARTICLE	IF	CITATIONS
307	A Case of IgG4-Related Disease: A Unique Presentation of a Rare Entity. American Journal of Gastroenterology, 2015, 110, S109-S110.	0.4	0
308	Recurrent Post-partum Jaundice: Rare Genetic Disorder With Novel Genetic Mutations Identified. American Journal of Gastroenterology, 2015, 110, S397.	0.4	0
309	Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. Gastroenterology and Hepatology, 2010, 6, 1-16.	0.1	0
310	Delta virus infection: epidemiology and initiatives to intercept it. Gastroenterology and Hepatology, 2013, 9, 589-91.	0.1	0
311	1066. Immune Escape Mutant Detection Using Commercially Available Methods for Hepatitis B Surface Antigen Serological Testing. Open Forum Infectious Diseases, 2020, 7, S562-S562.	0.9	0
312	Current developments in the treatment of hepatitis and hepatobiliary disease. Clinical Advances in Hematology and Oncology, 2006, 4, 511-2.	0.3	0
313	Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol-associated liver disease need our attention. Hepatology, 2022, 76, E7-E8.	7.3	0
314	Title is missing!. , 2019, 14, e0220612.		0
315	Title is missing!. , 2019, 14, e0220612.		0
316	Title is missing!. , 2019, 14, e0220612.		0
317	Title is missing!. , 2019, 14, e0220612.		0
318	Chronic Hepatitis B Viral Infection. , 0, , 636-641.		0